TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Nov 13, 2026, 5:37 PM ETResultsRead the original at globenewswire.com

Good for TRXB

TRB-061 showed early effects in people, and cash through the second half of 2029 supports TRex Bio's research. The result is still early, with more TRB-061 data expected by mid-2027.

TRXB · TRex Bio, Inc.

AI read · Good for TRXB

The AI's read

The human findings show TRB-061 affected the intended immune cells, giving the program early evidence in people. Phase 1a is an early study, and more results for atopic dermatitis are expected by mid-2027. Cash through 2029 gives TRex Bio time to run those studies and advance TRB-071.

Get alerts for TRXB

Follow TRex Bio, Inc. (TRXB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TRXB

Free on the App Store and Google Play, or on the web.